Dabrafenib, Vemurafenib

Summary

Vemurafenib and dabrafenib are both BRAF kinase inhibitors useful in the treatment of metastatic melanoma. Metastatic melanoma is often driven by activating mutations in the BRAF kinase gene, such as the V600E mutation that both drugs target.

Key Points

• Vemurafenib / Dabrafenib
  • Mechanism
    • BRAF kinase inhibitor
      • Small molecule inhibitors of BRAF+ melanoma
      • VEmuRAF-enib is for V600E-mutated BRAF inhibition
  • Clinical use
    • Metastatic melanoma
      • Metastatic melanoma is often driven by an activation mutation in BRAF